T h e r a p e u t i c I n d e x 139 Composition Each Liv.52 HB capsule contains: Exts. Mustaka (Cyperus rotundus). ............................... 125 mg Nagaramustaka (Cyperus scariosus).................. 125 mg Clinical Pharmacology Liv.52 HB has antiviral, immunomodulatory, anti-inflammatory, and hepatoprotective actions. Liv.52 HB is proven to have a triple mode of action in the management of hepatitis B: • Liv.52 HB inhibits HBsAg binding to its receptor, suggesting its role in inhibiting HBV at the entry level. • Cell line studies demonstrate that Liv.52 HB exhibits strong anti-HBV property by inhibiting the secretion of hepatitis B surface antigen (HBsAg), and this action is targeted at the transcription level. Both S and pre-S antigen secretion could be inhibited by Liv.52 HB in liver cells with integrated HBV DNA. • Also, Liv.52 HB inhibits the activity of reverse transcriptase enzyme. The hepatoprotective effect of Liv.52 HB reverses the oxidative damage to hepatocytes, which hastens the recovery period and ensures early restoration of hepatic functions. Liv.52 HB protects the hepatic parenchyma and promotes hepatocellular regeneration, possibly due to its antiperoxidative and antiviral actions. Indication Hepatitis B infection. Dosage 1 to 2 capsules twice daily after meals. Adverse Effects No adverse effects have been reported. Liv.52 HB® (capsule) Effective management of Hepatitis B Liv.52 HB, a phytopharmaceutical formulation, is recommended for the treatment of hepatitis B. Liv.52 HB helps manage hepatitis B infection through its antiviral, immunomodulatory, anti-inflammatory, and hepatoprotective actions. Liv.52 HB is well-tolerated, as no serious biochemical abnormalities are experienced by patients.
RkJQdWJsaXNoZXIy MjMwNjM2Nw==